Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
Critical Limb Ischemia, Buerger's Disease
About this trial
This is an interventional treatment trial for Critical Limb Ischemia focused on measuring critical limb ischemia, Buerger's disease, bone marrow derived mesenchymal stem cell
Eligibility Criteria
Inclusion Criteria: Males or females (willing to use accepted methods of contraception during the course of the study) in the age group of 18-65 years. Buerger's disease as diagnosed by Shionoya criteria Patients should have at least one ulcer (target ulcer): area between 0.5 to 10 cm2 (both inclusive) Ankle Brachial Pressure Index (ABPI) ≤ 0.6. If ABPI is ≥ 1.1 then Toe Brachial Index (TBI) will be performed and TBI should be ≤ 0.5 Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits Exclusion Criteria: Patients diagnosed with atherosclerotic peripheral arterial disease Patients eligible for surgical or percutaneous revascularization Patients with a history of participating in another stem cell trial or therapy within 3 months Patients who are unsuitable to participate the clinical trial as determined by investigators
Sites / Locations
- Hospital Canselor Tunku Mukhriz
Arms of the Study
Arm 1
Experimental
Stempeucel®
Stempeucel® (Ex-vivo cultured MSCs) supplied in 15 ml cryo bags consisting of 200 million or 150 million MSCs, 85% PlasmaLyte-A, 5% HSA and 10% DMSO in a total volume of 15 ml. Following thawing, 35 ml of PlasmaLyte A will be added to the Stempeucel® to make a total volume of 50 ml. The final concentration of components will be 1.5% HSA and 3% DMSO.